Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARQ761 + Telaglenastat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARQ761 | beta-lapachone|ARQ-761 | ARQ761 (beta-lapachone) is metabolized intracellularly by NQO1, generating reactive oxygen species, which leads to DNA damage and PARP1 hyperactivation and potentially results in increased death of NQO1-expressing tumor cells (PMID: 26602448, PMID: 31858276, PMID: 30617135). | ||
Telaglenastat | CB-839 | Glutaminase Inhibitor 3 | Telaglenastat (CB-839) binds to and inhibits glutaminase, preventing the conversion of glutamine to glutamate, which results in a decrease in cell proliferation (PMID: 31980651). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|